Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21,263 | 4 | 65.9% |
| Consulting Fee | $10,125 | 4 | 31.4% |
| Debt forgiveness | $849.42 | 1 | 2.6% |
| Food and Beverage | $15.96 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $31,388 | 8 | $0 (2019) |
| Optos, Inc. | $849.42 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $15.96 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $849.42 | 1 | Optos, Inc. ($849.42) |
| 2019 | $21,263 | 4 | Novo Nordisk AS ($21,263) |
| 2017 | $10,141 | 5 | Novo Nordisk AS ($10,125) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/30/2023 | Optos, Inc. | PANORAMIC OPHTHALMOSCOPE (Device) | Debt forgiveness | Cash or cash equivalent | $849.42 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/10/2019 | Novo Nordisk AS | Tresiba (Drug) | — | Cash or cash equivalent | $5,287.50 | Research |
| Study: NN1250-4252 • Category: Diabetes | ||||||
| 05/10/2019 | Novo Nordisk AS | Tresiba (Drug) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: NN1250-4252 • Category: Diabetes | ||||||
| 02/04/2019 | Novo Nordisk AS | Tresiba (Drug) | — | Cash or cash equivalent | $5,850.00 | Research |
| Study: NN1250-4252 • Category: Diabetes | ||||||
| 02/04/2019 | Novo Nordisk AS | Tresiba (Drug) | — | Cash or cash equivalent | $5,625.00 | Research |
| Study: NN1250-4252 • Category: Diabetes | ||||||
| 06/21/2017 | Novo Nordisk AS | Tresiba (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 06/05/2017 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), JANUMET, PNEUMOVAX 23 | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/12/2017 | Novo Nordisk AS | Tresiba (Drug) | Consulting Fee | Cash or cash equivalent | $5,175.00 | General |
| Category: Diabetes | ||||||
| 01/12/2017 | Novo Nordisk AS | Tresiba (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: Diabetes | ||||||
| 01/12/2017 | Novo Nordisk AS | Tresiba (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN1250-4252 | Novo Nordisk AS | $21,263 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 57 | 65 | $17,615 | $4,422 |
| 2022 | 3 | 86 | 109 | $22,926 | $5,930 |
| 2021 | 5 | 129 | 172 | $34,947 | $9,875 |
| 2020 | 5 | 139 | 181 | $29,800 | $6,206 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 65 | $17,615 | $4,422 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 57 | 58 | $15,718 | $4,061 | 25.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 34 | $4,080 | $1,058 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 17 | $3,128 | $811.14 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 62 | 71 | $18,468 | $5,248 | 28.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 18 | 22 | $5,422 | $1,618 | 29.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 17 | 46 | $5,505 | $1,359 | 24.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 19 | 20 | $3,281 | $991.80 | 30.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 13 | $2,271 | $658.20 | 29.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 68 | 76 | $18,316 | $3,478 | 19.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 16 | 50 | $6,000 | $1,447 | 24.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 19 | 19 | $2,904 | $746.64 | 25.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 18 | 18 | $1,382 | $358.19 | 25.9% |
| 92250 | Photography of the retina | Facility | 2020 | 18 | 18 | $1,198 | $175.75 | 14.7% |
About Dr. David Ziemer, MD
Dr. David Ziemer, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700834330.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ziemer, MD has received a total of $32,253 in payments from pharmaceutical and medical device companies, with $849.42 received in 2023. These payments were reported across 10 transactions from 3 companies. The most common payment nature is "" ($21,263).
As a Medicare-enrolled provider, Ziemer has provided services to 411 Medicare beneficiaries, totaling 527 services with total Medicare billing of $26,432. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Atlanta, GA
- Active Since 05/05/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1700834330
Products in Payments
- Tresiba (Drug) $31,388
- PANORAMIC OPHTHALMOSCOPE (Device) $849.42
- JANUVIA (Drug) $15.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Atlanta
Bruce Bode, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2.9M
David Robertson, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2.0M
Jonathan Ownby, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $297,304
Guillermo Umpierrez, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $103,343
Francisco Pasquel, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $88,785
Priyathama Vellanki, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $61,485